SynthesisJournal of Alzheimer's disease : JAD2017
A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers.
Synthesis in Journal of Alzheimer's disease : JAD, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Chronic periodontitis and systemic inflammation in the elderly: implications for neurodegeneration.Journal of neuroinflammation · 2026Review
- A seven-year longitudinal study of the Alzheimer's disease blood metabolome.medRxiv : the preprint server for health sciences · 2025Article
- Brain and retina in Alzheimer's disease: Pathological intersections and estimates from imaging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Neurite Degradation Mediates the Effect of Amyloid Deposition on Global Cognition in Asymptomatic Older Adults.medRxiv : the preprint server for health sciences · 2025Article
- Deep-Diffeomorphic Networks for Conditional Brain Templates.Human brain mapping · 2025Article
- Quantitative brain volumetry in neurological disorders: from disease mechanisms to software solutions.Polish journal of radiology · 2025Review
- Timing of Alzheimer's disease biomarker progressions: A two-decade observational study from the Alzheimer's Disease Neuroimaging Initiative (ADNI).Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Observational
- Deep learning for the harmonization of structural MRI scans: a survey.Biomedical engineering online · 2024Review
- Estimating individual trajectories of structural and cognitive decline in mild cognitive impairment for early prediction of progression to dementia of the Alzheimer's type.Scientific reports · 2024Article
- Mass spectrometry in cerebrospinal fluid uncovers association of glycolysis biomarkers with Alzheimer's disease in a large clinical sample.Scientific reports · 2023Article
- Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression.Brain : a journal of neurology · 2023Article
- Outcome measures for Alzheimer's disease: A global inter-societal Delphi consensus.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Dementia Prevention Research Clinic: a longitudinal study investigating factors influencing the development of Alzheimer's disease in Aotearoa, New Zealand.Journal of the Royal Society of New Zealand · 2023Article
- REDACS: Regional emergency-driven adaptive cluster sampling for effective COVID-19 management.Stochastic analysis and applications · 2023Article
- Associations Between Insulin-Like Growth Factor-1 and Resting-State Functional Connectivity in Cognitively Unimpaired Midlife Adults.Journal of Alzheimer's disease : JAD · 2023Article
- Selective impairment of circuits between prefrontal cortex glutamatergic neurons and basal forebrain cholinergic neurons in a tauopathy mouse model.Cerebral cortex (New York, N.Y. : 1991) · 2022Article
- Longitudinal surface-based spatial Bayesian GLM reveals complex trajectories of motor neurodegeneration in ALS.NeuroImage · 2022Article
- Alzheimer's Disease: Epidemiology and Clinical Progression.Neurology and therapy · 2022Review
- Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease.Alzheimer's research & therapy · 2022Review
- A Long Short-Term Memory Biomarker-Based Prediction Framework for Alzheimer's Disease.Sensors (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive and fatal neurodegenerative disease, with no effective treatment or cure. A gold standard therapy would be treatment to slow or halt disease progression; however, knowledge of causation in the early stages of AD is very limited. In order to determine effective endpoints for possible therapies, a number of quantitative surrogate markers of disease progression have been suggested, including biochemical and imaging biomarkers. The dynamics of these various surrogate markers over time, particularly in relation to disease development, are, however, not well characterized. We reviewed the literature for studies that measured cerebrospinal fluid or plasma amyloid-β and tau, or took magnetic resonance image or fluorodeoxyglucose/Pittsburgh compound B-positron electron tomography scans, in longitudinal cohort studies. We summarized the properties of the major cohort studies in various countries, commonly used diagnosis methods and study designs. We have concluded that additional studies with repeat measures over time in a representative population cohort are needed to address the gap in knowledge of AD progression. Based on our analysis, we suggest directions in which research could move in order to advance our understanding of this complex disease, including repeat biomarker measurements, standardization and increased sample sizes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.